SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
BioNTech CEO Ugur Sahin and Chief MEdical Officer Özlem Türeci.
C-suite
BioNTech Founders To Leave Famed mRNA Biotech for New Venture
The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.
March 10, 2026
 · 
2 min read
 · 
Annalee Armstrong
change business management, businessman turn gear cog to manage change direction arrows, professional or expertise to manage company transformation or implement new process concept vector illustration
Manufacturing
Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032
Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.
March 10, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Closeup of businessman give money to robot. Man pass banknote bribe to robotic assistant. AI and technology. Vector illustration.
Funding
AI-Focused Fund Breakout Raises $114M To Support Early-Stage Biotechs
Breakout Ventures’ focus on early-stage companies stands out as more and more investors elect to save their dollars for derisked assets.
March 10, 2026
 · 
2 min read
 · 
Tristan Manalac
NextGen
Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead
Stylus Medicine, a member of BioSpace’s NextGen Class of 2026, launched in May 2025 to develop new, less complex genetic medicines. The company’s in vivo approach has attracted “intense” interest from Big Pharma.
March 10, 2026
 · 
2 min read
 · 
Annalee Armstrong
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Duchenne muscular dystrophy
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data
Dyne Therapeutics is plotting an approval application for z-rostudirsen in the back half of 2026—a push that will only be bolstered by the departure of controversial CBER chief Vinay Prasad, according to analysts at Stifel.
March 10, 2026
 · 
3 min read
 · 
Tristan Manalac
Concept World kidney day, handcraft paper blue kidneys and stethoscope on yellow background. Copy space. Banner.
IgA nephropathy
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetacicept in IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the end of March.
March 10, 2026
 · 
2 min read
 · 
Tristan Manalac
Flat 3d isometric business people came from different way but have same target. Business team and target concept.
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
Single-trial approvals are raising the bar on trial design and execution. The new paradigm is pushing sponsors to plan earlier, step up their data and risk‑based quality management and use modeling and AI to generate one compelling, regulator‑ready evidence package.
March 10, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Concept 3d illustration of a collocated containers as though a computer game due to imports tariffs.
Manufacturing
Nonprofit Aims To Modernize Manufacturing by Clearing Capital Hurdle
Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments in continuous manufacturing.
March 10, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Businessman looks at the rugged road
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a Phase 1 trial.
March 9, 2026
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS